Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication

Hepatology

Volumn 56, Issue 6, 2012, Pages 2082-2093

  Metz, Philippe ^a   Dazert, Eva ^a,b   Ruggieri, Alessia ^a   Mazur, Johanna ^a,d   Kaderali, Lars ^a,e   Kaul, Artur ^a,f   Zeuge, Ulf ^a,g   Windisch, Marc P ^a,i   Trippler, Martin ^c   Lohmann, Volker ^a   Binder, Marco ^a   Frese, Michael ^a,h   Bartenschlager, Ralf ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f ViroLogik GmbH   (Germany)

^g Department of Urology Hospital of the Canton of Zug   (Switzerland)

^h UNIVERSITY OF CANBERRA   (Australia)

ⁱ Institute Pasteur Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEAT 3; MESSENGER RNA; PHOSPHOLIPID SCRAMBLASE 1; PROTEIN KINASE R; STAT2 PROTEIN; TRIPARTITE MOTIF CONTAINING 14; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; GAIN OF FUNCTION MUTATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIGENS, DIFFERENTIATION; CARRIER PROTEINS; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHOLIPID TRANSFER PROTEINS; REPLICON; RNA INTERFERENCE; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED; UP-REGULATION; VIRUS REPLICATION;

EID: 84870554890     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25908     Document Type: Article

References (33)

1. Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 2001; 82: 723-733.
2. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. HEPATOLOGY 2002; 35: 694-703.
3. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
4. Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012; 36: 663-683.
5. Jo J, Aichele U, Kersting N, Klein R, Aichele P, Bisse E, et al. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology 2009; 136: 1391-1401.
6. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
7. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity 2006; 25: 373-381.
8. Haller O, Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011; 31: 79-87.
9. Itsui Y, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Koyama T, et al. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat 2006; 13: 690-700.
10. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472: 481-485.
11. Helbig KJ, Lau DT, Semendric L, Harley HA, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. HEPATOLOGY 2005; 42: 702-710.
12. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 2011; 85: 12881-12889.
13. Vrolijk JM, Kaul A, Hansen BE, Lohmann V, Haagmans BL, Schalm SW, et al. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J Virol Methods 2003; 110: 201-209.
14. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 2003; 77: 3007-3019.
15. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
16. Cheney IW, Lai VC, Zhong W, Brodhag T, Dempsey S, Lim C, et al. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol 2002; 76: 11148-11154.
17. Han JQ, Wroblewski G, Xu Z, Silverman RH, Barton DJ. Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites. J Interferon Cytokine Res 2004; 24: 664-676.
18. Yao L, Dong H, Zhu H, Nelson D, Liu C, Lambiase L, et al. Identification of the IFITM3 gene as an inhibitor of hepatitis C viral translation in a stable STAT1 cell line. J Viral Hepat 2011; 18: e523-529.
19. Gale MJ, Jr., Korth MJ, Tang NM, Tan SL, Hopkins DA, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227.
20. Pflugheber J, Fredericksen B, Sumpter R Jr, Wang C, Ware F, Sodora DL, et al. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A 2002; 99: 4650-4655.
21. Kubicka S, Trautwein C, Niehof M, Manns M. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations. HEPATOLOGY 1997; 25: 867-873.
22. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011; 9: 32-45.
23. Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR, et al. IFIT1 is an antiviral protein that recognizes 5′-triphosphate RNA. Nat Immunol 2011; 12: 624-630.
24. George CX, Wagner MV, Samuel CE. Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing. J Biol Chem 2005; 280: 15020-15028.
25. Yu SH, Nagayama K, Enomoto N, Izumi N, Marumo F, Sato C. Intrahepatic mRNA expression of interferon-inducible antiviral genes in liver diseases: dsRNA-dependent protein kinase overexpression and RNase L inhibitor suppression in chronic hepatitis C. HEPATOLOGY 2000; 32: 1089-1095.
26. Ruggieri A, Dazert E, Metz P, Hofmann S, Bergeest J, Mazur J, et al. Dynamic oscillation of translation and stress granule formation mark the cellular response to virus infection. Cell Host Microbe 2012 [Epub ahead of print].
27. Sahu SK, Gummadi SN, Manoj N, Aradhyam GK. Phospholipid scramblases: an overview. Arch Biochem Biophys 2007; 462: 103-114.
28. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 5487-5492.
29. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-350.
30. Liu XY, Chen W, Wei B, Shan YF, Wang C. IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol 2011; 187: 2559-2568.
31. Ozato K, Shin DM, Chang TH, Morse HC, 3rd. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 2008; 8: 849-860.
32. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 2011; 7: e1001258.
33. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R. Persistance of HCV in quiescent hepatic cells during an interferon-induced antiviral response. Gastroenterology 2012 [Epub ahead of print].